Reuters logo
BRIEF-Allergan and Editas Medicine enter into strategic research and development alliance
2017年3月14日 / 中午12点13分 / 6 个月前

BRIEF-Allergan and Editas Medicine enter into strategic research and development alliance

March 14 (Reuters) - Allergan Plc

* Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases

* Under terms of agreement, Editas medicine will receive an upfront payment of $90 million for development of five candidate programs

* Editas Medicine has potential to earn additional payments for achieving important near-term milestones specifically related to LCA10

* Editas medicine will also be eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis

* Allergan will have option to license up to five programs and will be responsible for development and commercialization of optioned products Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below